Marker Therapeutics, Inc. (MRKR)
NASDAQ: MRKR · Real-Time Price · USD
1.140
-0.090 (-7.32%)
At close: Apr 1, 2025, 4:00 PM
1.274
+0.134 (11.74%)
After-hours: Apr 1, 2025, 4:38 PM EDT

Marker Therapeutics Stock Forecast

MRKR's stock price has decreased by -74.19% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

The 3 analysts with 12-month price forecasts for Marker Therapeutics stock have an average target of 13.17, with a low estimate of 8.00 and a high estimate of 19. The average target predicts an increase of 1,055.26% from the current stock price of 1.14.

Analyst Consensus: Strong Buy
Target Low Average Median High
Price $8.00 $13.17 $12.5 $19
Change +601.75% +1055.3% +996.49% +1566.7%

Analyst Ratings

The average analyst rating for Marker Therapeutics stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating Nov '24Dec '24Jan '25Feb '25Mar '25Apr '25
Strong Buy 111123
Buy 000000
Hold 000000
Sell 000000
Strong Sell 000000
Total 111123

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
WBB Securities
WBB Securities
Strong Buy
Reiterates
$13
Strong Buy Reiterates $13 +996.49% Apr 1, 2025
Canaccord Genuity
Canaccord Genuity
Strong Buy
Initiates
$8
Strong Buy Initiates $8 +601.75% Mar 5, 2025
Ladenburg Thalmann
Ladenburg Thalmann
Strong Buy
Maintains
$11$19
Strong Buy Maintains $11$19 +1,566.67% Oct 21, 2024
Ladenburg Thalmann
Ladenburg Thalmann
Strong Buy
Initiates
$11
Strong Buy Initiates $11 +864.91% Apr 30, 2024
Roth Capital
Roth Capital
Hold
Downgrades
$30$10
Hold Downgrades $30$10 +777.19% Feb 17, 2022
More Analyst Ratings

Financial Forecast

Revenue This Year
3.33M
from 6.59M
Decreased by -49.52%
Revenue Next Year
1.97M
from 3.33M
Decreased by -40.88%
EPS This Year
-1.80
from -1.19
EPS Next Year
-2.01
from -1.80
Fiscal Year FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026 FY 2027
Period Ending Dec 31, 2020 Dec 31, 2021 Dec 31, 2022 Dec 31, 2023 Dec 31, 2024 Dec 31, 2025 Dec 31, 2026 Dec 31, 2027
Revenue
466.79K1.24M3.51M3.31M6.59M3.33M1.97M38.73M
Revenue Growth
118.95%166.01%182.96%-5.76%99.06%-49.52%-40.88%1,869.04%
EPS
-6.10-5.47-3.59-0.94-1.19-1.80-2.01-1.15
EPS Growth
--------
Forward PE
--------
No. Analysts -----553
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue 20252026202720282029
High 6.1M 6.1M 39.9M
Avg 3.3M 2.0M 38.7M
Low n/a n/a 37.2M

Revenue Growth

Revenue Growth 20252026202720282029
High
-7.8%
82.6%
1,927.0%
Avg
-49.5%
-40.9%
1,869.0%
Low - -
1,791.9%

EPS Forecast

EPS 20252026202720282029
High -0.68 -0.47 -1.19
Avg -1.80 -2.01 -1.15
Low -2.39 -2.80 -1.11

EPS Growth

EPS Growth 20252026202720282029
High - - -
Avg - - -
Low - - -
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.